| Literature DB >> 28454567 |
Daniel N Qekwana1, James W Oguttu2, Fortune Sithole1,3, Agricola Odoi4,5.
Abstract
BACKGROUND: Antimicrobial resistance in staphylococci, often associated with treatment failure, is increasingly reported in veterinary medicine. The aim of this study was to investigate patterns and predictors of antimicrobial resistance among Staphylococcus spp. isolates from canine samples submitted to the bacteriology laboratory at the University of Pretoria academic veterinary hospital between 2007 and 2012. Retrospective data of 334 Staphylococcus isolates were used to calculate the proportion of samples resistant to 15 antimicrobial agents. The Cochran-Armitage trend test was used to investigate temporal trends and logistic regression models were used to investigate predictors of antimicrobial resistance in Staphylococcus aureus and Staphylococcus pseudintermedius.Entities:
Keywords: AMR; Antimicrobial resistance; MDR; Staphylococcus aureus; Staphylococcus pseudintermedius; canine; dogs; multidrug resistance; predictors; risk factors
Mesh:
Substances:
Year: 2017 PMID: 28454567 PMCID: PMC5410067 DOI: 10.1186/s12917-017-1034-3
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Fig. 1Proportions of S. aureus and S. pseudintermedius samples resistant to each of the 15 antimicrobials tested at the University of Pretoria bacteriology laboratory, 2007 and 2012
Trends in antimicrobial resistance of S. aureus from samples tested at the University of Pretoria bacteriology laboratory, 2007–2012
| Group | Antimicrobials | Resistance to antimicrobial agents by year |
a
| |||||
|---|---|---|---|---|---|---|---|---|
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | |||
| β-lactams | Penicillin | 75.0 (6/8) | 80.0 (12/15) | 63.6 (7/11) | 50.0 (5/10) | 50.0 (3/6) | 50.0 (3/6) | 0.089 |
| Ampicillin | 75.0 (6/8) | 80.0 (12/15) | 63.6 (7/11) | 60.0 (6/10) | 50.0 (3/6) | 50.0 (3/6) | 0.124 | |
| Cephalothin | 25.0 (2/8) | 6.7 (1/15) | 9.1 (1/11) | 10.0 (1/10) | 0.0 (0/6) | 0.0 (0/6) | 0.181 | |
| Aminoglycosides | Amikacin | 0.0 (0/8) | 20.0 (3/15) | 9.1 (1/11) | 0.0 (0/10) | 0.0 (0/6) | 0.0 (0/6) | 0.258 |
| Gentamicin | 12.5 (1/8) | 20.0 (3/15) | 9.1 (1/11) | 0.0 (0/10) | 0.0 (0/6) | 0.0 (0/6) | 0.098 | |
| Kanamycin | 25.0 (2/8) | 26.7 (4/15) | 9.1 (1/11) | 0.0 (0/10) | 0.0 (0/6) | 0.0 (0/6) | 0.017 | |
| Tetracyclines | Doxycycline | 37.5 (3/8) | 26.7 (4/15) | 36.4 (4/11) | 20.0 (2/10) | 0.0 (0/6) | 0.0 (0/6) | 0.041 |
| Fluoroquinolones | Enrofloxacin | 0.0 (0/8) | 6.7 (1/15) | 0.0 (0/11) | 0.0 (0/10) | 16.7 (1/6) | 50.0 (3/6) | 0.005 |
| Orbifloxacin | 12.5 (1/8) | 20.0 (3/15) | 9.1 (1/11) | 0.0 (0/10) | 16.7 (1/6) | 33.3 (2/6) | 0.718 | |
| Potentiated-sulfas | Co-trimoxazoleb | 37.5 (3/8) | 33.3 (5/15) | 27.3 (3/11) | 10.0 (1/10) | 0.0 (0/6) | 16.7 (1/6) | 0.067 |
| Amphenicols | Chloramphenicol | 33.3 (1/3) | 20.0 (3/15) | 9.1 (1/11) | 10.0 (1/10) | 40.0 (2/5) | 33.3 (2/6) | 0.552 |
| Macrolides | Tylosin | 37.5 (3/8) | 33.3 (5/15) | 0.0 (0/11) | 10.0 (1/10) | 0.0 (0/6) | 0.0 (0/6) | 0.008 |
| Aminoglycoside-lincosamides | Lincospectinc | 37.5 (3/8) | 80.0 (12/15) | 54.6 (6/11) | 70.0 (7/10) | 50.0 (3/6) | 83.3 (5/6) | 0.478 |
| Lincosamides | Clindamycin | 50.0 (4/8) | 60.0 (9/15) | 45.5 (5/11) | 60.0 (6/10) | 50.0 (3/6) | 33.3 (2/6) | 0.552 |
| Others | Amoxicillin/clavulanic acid | 37.5 (3/8) | 33.3 (5/15) | 9.1 (1/11) | 0.0 (0/10) | 0.0 (0/6) | 16.7 (1/6) | 0.032 |
a P-values of CAT Test= P-value of Cochran-Armitage trend test
bCo-trimoxazole = Trimethoprim-sulphamethoxazole
cLincospectin = Espectinomycine-lincomycine
Fig. 2Antimicrobial agents showing significant temporal trends in resistance based on the Cochran-Armitage trend tests among the S. aureus isolates from canine samples tested at the University of Pretoria bacteriology laboratory, 2007–2012
Trends in antimicrobial susceptibility of S. pseudintermedius to antimicrobial agents from samples tested at the University of Pretoria academic veterinary laboratory, 2007–2012
| Group | Antimicrobial | Resistance to antimicrobial agents by year |
a
| |||||
|---|---|---|---|---|---|---|---|---|
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | |||
| β-lactams | Penicillin | 37.5 (15/40) | 58.6 (34/58) | 50.0 (30/60) | 51.2 (22/43) | 73.2 (30/41) | 55.6 (16/36) | 0.052 |
| Ampicillin | 50.0 (20/40) | 56.9 (33/58) | 53.3 (32/60) | 55.8 (24/43) | 73.2 (30/41) | 61.1 (22/36) | 0.104 | |
| Cephalothin | 7.5 (3/40) | 5.2 (3/58) | 5.0 (3/60) | 2.3 (1/43) | 7.3 (3/41) | 2.8 (1/36) | 0.555 | |
| Aminoglycosides | Amikacin | 0.0 (0/40) | 13.8 (8/58) | 3.3 (2/60) | 0.0 (0/43) | 4.9 (2/41) | 2.8 (1/36) | 0.382 |
| Gentamicin | 0.0 (0/40) | 10.3 (6/53) | 3.3 (2/60) | 0.0 (0/43) | 2.4 (1/41) | 5.6 (2/36) | 0.777 | |
| Kanamycin | 2.5 (1/40) | 3.5 (2/58) | 8.3 (5/60) | 4.7 (2/43) | 4.9 (2/41) | 5.6 (2/36) | 0.612 | |
| Tetracyclines | Doxycycline | 12.5 (5/40) | 22.4 (13/58) | 15.0 (9/60) | 2.3 (1/43) | 17.1 (7/41) | 8.3 (3/36) | 0.213 |
| Fluoroquinolones | Enrofloxacin | 5.0 (2/40) | 5.2 (3/58) | 6.7 (4/60) | 4.7 (2/43) | 4.9 (2/41) | 16.7 (6/36) | 0.122 |
| Orbifloxacin | 0.0 (0/40) | 3.5 (2/58) | 6.7 (4/60) | 0.0 (0/43) | 7.3 (3/41) | 11.1 (4/36) | 0.042 | |
| Potentiated sulfas | Co-trimoxazoleb | 2.5 (1/40) | 5.2 (3/58) | 20.0 (3/60) | 14.0 (2/41) | 17.1 (7/41) | 22.2 (8/36) | 0.004 |
| Amphenicols | Chloramphenicol | 4.8 (1/21) | 7.0 (4/57) | 5.0 (3/60) | 4.9 (2/41) | 12.8 (5/36) | 5.6 (2/36) | 0.626 |
| Macrolides | Tylosin | 7.5 (3/40) | 6.9 (4/58) | 6.7 (4/60) | 7.0 (3/43) | 9.8 (4/41) | 5.6 (2/36) | 1 |
| Aminoglycoside-lincosamides | Lincospectinc | 22.5 (9/40) | 48.3 (28/58) | 26.7 (16/60) | 39.5 (17/43) | 58.5 (24/41) | 38.9 (14/36) | 0.066 |
| Lincosamides | Clindamycin | 22.5 (9/40) | 25.9 (15/58) | 26.7 (16/60) | 32.6 (14/43) | 58.5 (24/41) | 27.8 (10/36) | 0.022 |
| Others | Amoxicillin/clavulanic acid | 22.5 (9/40) | 6.9 (4/58) | 5.0 (3/60) | 2.3 (1/43) | 17.1 (7/41) | 5.6 (2/36) | 0.225 |
a P-value of CAT Test = P-value of Cochran-Armitage trend test
bCo-trimoxazole = Trimethoprim-sulphamethoxazole
cLincospectin = Espectinomycine-lincomycine
Fig. 3Antimicrobial agents showing significant temporal trends in resistance based on the Cochran-Armitage trend tests among the S. pseudintermedius isolates from canine samples tested at the University of Pretoria bacteriology laboratory, 2007–2012
Fig. 4Proportions of S. aureus and S. pseudintermedius isolates resistant to at least one antibiotic from samples tested at the University of Pretoria bacteriology laboratory, 2007–2012
Fig. 5Proportions of multidrug resistant S. aureus and S. pseudintermedius isolates from samples tested at the University of Pretoria veterinary bacteriology laboratory, 2007–2012